Catalyst Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $597M+21.4% YoYTTM through 31 Mar 2026
Net Income $221.3M+35.0% YoYTTM through 31 Mar 2026
Free Cash Flow $208.1MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 85.2% |
| EBITDA Margin | 44.8% |
| Operating Margin | 43.8% |
| Net Margin | 37.1% |
Returns
22.5%ROE
19.4%ROA
86.2%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.08x
Net Debt-$709.2Mnet cash position
Cash & Equivalents$755.9M
Quality Metrics
Altman Z-Score19.92
Piotroski F-Score5 / 9
FCF Margin34.9%
Rule of 4041.4
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $589M
Diluted EPS$1.73TTMFY2025: $1.68
Dividend
No dividend
Capital Allocation
R&D Spend$11.5M
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| FIRDAPSE Product Revenue | $358.4M | +17.1% | View detailsExpected to maintain strong organic growth and benefit from reduced royalty rates in 2026. |
| AGAMREE Product Revenue | $117.1M | +154.3% | View detailsSustained market uptake and increasing prescriber engagement expected to drive future growth. |
| FYCOMPA Product Revenue | $113.3M | -17.4% | View detailsExpected to decline significantly in 2026 due to multiple generic entrants. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.